Innovative horizons: Advancing platinum-resistant ovarian cancer (PROC) treatment
with antibody-drug conjugates (ADCs)
Industry Supported Symposium

Activity Overview

Daiichi-Sankyo and MSD welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the enduring education materials for the Innovative horizons: Advancing platinum-resistant ovarian cancer (PROC) treatment with antibody-drug conjugates (ADCs) Industry Supported Symposium presented at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa on Wednesday, November 5, 2025.

This industry satellite symposium is organised and funded by Daiichi Sankyo and MSD.

Target Audience

Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.

Learning Objectives

Upon completion of the activities in this series, learners will be able to:

• Explore unmet medical needs in patients with PROC
• Review emerging targets and clinical developments with ADCs in PROC
• Discuss future challenges and how we can learn from the use of ADCs in other indications

Agenda

Innovative horizons: Advancing platinum-resistant ovarian cancer (PROC) treatment with antibody-drug conjugates (ADCs), presented an Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

This session is not included in the main event CME/CPD credit.

Enduring education materials will be available for six months.